“Epilepsy is really a classical neurological disorder,” Lars Pinborg told the audience at the European College of Neuropsychopharmacology (ECNP) annual conference on Sunday. “Or is it?” Pinborg, of Rigshospitalet's The Neuroscience Center in Denmark, was chairing a session dedicated to an alternative hypothesis, summed up in the session title: “Is epilepsy a psychiatric disorder?” Read More
Researchers from Meiragtx Ltd. presented preclinical data on a new and optimized gene therapy based on a mini ATP7B gene for the potential treatment of Wilson’s disease (WD), a rare (1:30,000) autosomal recessive genetic disease caused by loss-of-function mutations in ATP7B, leading to a pathologically high amount of copper in the liver and brain. Read More
Nanoviricides Inc. has completed its IND-enabling preclinical drug development tasks pertaining to NV-CoV-2 for the treatment of SARS-CoV-2 infection and is working to prepare an IND application to submit to the FDA. Read More
Anti-SARS-CoV-2 monoclonal antibody (MAb) pair COV2-2196 (tixagevimab, class I) and COV2-2130 (cilgavimab, class III) are human neutralizing Abs (nAbs) that target nonredundant, complementary epitopes within the receptor binding domain of SARS-CoV-2 spike protein (S-RBD). Read More
Akeso Inc. has received approval from China's National Medical Products Administration (NMPA) for a phase Ib/II trial of ivonescimab (AK-112) combined with drebuxelimab (AK-119) for the treatment of advanced solid tumors. Read More
Decibel Therapeutics Inc. has received clearance from the FDA for its IND application to initiate a phase I/II trial of DB-OTO in pediatric patients, potentially in infants younger than 2 years of age. Read More
Increasing evidence exists regarding estrogen receptor β (ERβ) playing a protective role in Alzheimer’s disease (AD) and its loss resulting in progressive neural cell body degeneration. Read More
Biomea Fusion Inc. has received IND clearance from the FDA to begin a phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic non-small-cell lung cancer (NSCLC), colorectal cancer, or pancreatic ductal adenocarcinoma with an activating KRAS mutation. Read More
Researchers at the University of Queensland have been awarded funding to advance work across mRNA research, cancer vaccines and single-cell genomic technologies. Read More
Preclinical data on a novel T-cell therapy based on engineered autologous regulatory T cells (GNTI-122, EngTregs) for the potential treatment of type 1 diabetes (T1D) were presented by Gentibio Inc. Read More
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new fused tetracyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1, MEKKK1) inhibitors reported to be useful for the treatment of cancer, diabetes, inflammation, infections, neurodegeneration and autoimmune, cardiovascular and reproductive disorders. Read More
Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharmaceutical Tech Co. Ltd. have divulged new polycyclic lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of small-cell lung cancer (SCLC). Read More
T-cell activation and function depend on Ca2+ signals and Ca2+ influx after antigen binding to the T-cell receptor (TCR) is mediated by store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane. Read More
Eccogene (Shanghai) Co. Ltd. has presented new GLP-1 receptor agonists reported to be useful for the treatment of diabetes, obesity, atherosclerosis, hypertension, stroke, Parkinson’s disease, diabetic kidney disease and liver disease. Read More
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged new theophine GLP-1 receptor agonists reported to be useful for the treatment of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, obesity, glucose intolerance, dyslipidemia, hyperinsulinemia and insulin resistance. Read More
To determine if long noncoding RNA (lncRNA) LINC01018 has a tumor-suppressing role in hepatocellular carcinoma (HCC), scientists at the Theodor Bilharz Research Institute and the American University in Cairo developed a therapeutic modality to treat mice with experimental disease. Read More
Medshine Discovery Inc. has presented new compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer. Read More
